Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Investigational arm: Tablets containing 250mg elemental calcium from Amorphous Calcium Carbonate (ACC).”In the company’s words, NCT06547151 on ClinicalTrials.gov
- Tested for
- Hypoparathyroidism
- Main trialPhase 2
- “This clinical trial aims to evaluate the efficacy and safety of AMOR-1, consisting of Amorphous Calcium Carbonate (ACC) as the active drug substance, in treating hypocalcemia in adults with hypoparathyroidism.”In the company’s words, NCT06547151 on ClinicalTrials.gov
Other drugs for Hypoparathyroidism
- PalopegteriparatideAscendis Pharma A/S · Phase 3
- CanvuparatideMBX Biosciences · Phase 3
- EncaleretCalcilytix Therapeutics, Inc., a BridgeBio company · Phase 3
- EneboparatideAlexion Pharmaceuticals, Inc. · Phase 3
- EXT608Extend Biosciences Inc. · Phase 2
Coming up1
- 30 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 30 Dec 2026 | Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026